Tumor Targeted Nanoparticles: A Modern Day Trojan Horse

Seminars in Thoracic and Cardiovascular Surgery

Volumn 23, Issue 1, 2011, Pages 10-11

  Gilmore, Denis ^a   Colson, Yolonda L ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Cancer; Nanoparticle; Tumor targeted

Indexed keywords

BLOOD CLOTTING FACTOR 5; CYCLODEXTRIN; GOLD NANOPARTICLE; MACROGOL; MESSENGER RNA; NANOCOATING; NANOPARTICLE; PACLITAXEL; PROTEIN RRM2; PROTHROMBIN; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CARDIOTOXICITY; CHEMICAL COMPOSITION; DIAGNOSTIC IMAGING; DRUG TARGETING; GENE MUTATION; GENE SILENCING; GENETIC SCREENING; HUMAN; HYPERHOMOCYSTEINEMIA; LYMPHADENOPATHY; MELANOMA; MICELLE; MOLECULAR BIOLOGY; NANOBIOTECHNOLOGY; NANOENGINEERING; NONHUMAN; PARTICLE SIZE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PNEUMONIA; RADIOFREQUENCY ABLATION; REPRODUCIBILITY; RETICULOENDOTHELIAL SYSTEM; SOLID TUMOR; SURFACE PROPERTY; THROMBOPHILIA; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG CARRIERS; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; NANOPARTICLES; NEOPLASMS; PREDICTIVE VALUE OF TESTS;

EID: 79960901684     PISSN: 10430679     EISSN: 15329488     Source Type: Journal    
DOI: 10.1053/j.semtcvs.2011.03.004     Document Type: Article

References (9)

1. Kim B.Y.S., Rutka J.T., Chan W.C.W. Nanomedicine. N Engl J Med 2010, 363:2434-2443.
2. Small is different: a science perspective on the regulatory challenges of the nanoscale Council of the Canadian Academies, Accessed July 2008. http://www.nanolawreport.com/JulyCanadaReport.pdf.
3. Peer D., Karp J.M., Hong S., et al. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007, 2:751-760.
4. Lammers T., Hannink W.E., Storm G. Tumor-targeted nanomedicines: principles and practice. Br J Cancer 2008, 99:392-397.
5. Macda H., Matsumura Y. Tumoritropic and lymphotropic principles of macromolecular drugs. Crit Rev Ther Drug Carrier Syst 1989, 6:193-210.
6. Libutti S.K., Paciotti G.F., Myer L., et al. Preliminary results of a phase I clinical trial of CYT-6091: a pegylated colloidal gold-TNF nanomedicine. J Clin Oncol 2007, 25(Suppl):163s.
7. Visaria R.K., Griffin R.J., Williams B.W., et al. Enhancement of tumor thermal therapy using gold nanoparticle-assisted tumor necrosis factor-alpha delivery. Mol Cancer Ther 2006, 5:1014-1020.
8. Posthuma-Trumpie G.A., Korf J., van Amerongen A.V. Lateral flow(immuno)assay: its strengths, weaknesses, opportunities and threats-a literature survey. Anal Bioanal Chem 2009, 393:569-582.
9. Davis M.E., Zuckerman J.E., Choi C.H.J., et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010, 464:1067-1070.